• Explore /
  • Poster
  • / The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (ΜΙLΟ)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (ΜΙLΟ)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Abstract Poster

Authors

Bradley Monk

Bradley J. Monk

University of Arizona Cancer Center, Phoenix, AZ

Bradley J. Monk , Rachel N. Grisham , Christian Marth , Susana N. Banerjee , Felix Hilpert , Robert L. Coleman , Eric Pujade-Lauraine , Sandro Pignata , Mansoor Raza Mirza , Amit M. Oza , Josep M. del Campo , Martin Klaus Oehler , Adam James , Janna Christy-Bittel , Emma Barrett , Adam P. Boyd , Ignace Vergote

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01849874

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5618)

DOI

10.1200/jco.2014.32.15_suppl.tps5618

Abstract #

TPS5618

Poster Bd #

396B

Abstract Disclosures

Similar Posters

First Author: Bradley J. Monk

First Author: Susana N. Banerjee

First Author: Susana N. Banerjee

First Author: Susana N. Banerjee